All In MedTech

FDA Clearance Tracker · P040013

GEM 21S (GROWTH-FACTOR ENHANCED MATRIX

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Nov 18, 2005 (this decision)Source: openFDAMethods & limitations

PMA

The decision

FDA number
P040013
Device name
GEM 21S (GROWTH-FACTOR ENHANCED MATRIX
Applicant location
Franklin, TN
Received
Mar 12, 2004
Decided
Nov 18, 2005
Decision
Approved
Supplements
29 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 872.3930

Every decision under product code NPZ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE GEM 21S (GROWTH-FACTOR ENHANCED MATRIX). THE DEVICE IS INDICATED TO TREAT THE FOLLOWING PERIODONTALLY RELATED DEFECTS: 1) INTRABONY PERIODONTAL DEFECTS 2) FURCATION PERIODONTAL DEFECTS 3) GINGIVAL RECESSION ASSOCIATED WITH PERIODONTAL DEFECTS.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NPZ. The earliest in FDA's data is P990033, decided Oct 25, 1999.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Lynch Biologics, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.